Navigation Links
ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
Date:10/15/2008

Solidifies Company's Leadership Position in Targeting Chemokine Receptor

CCR9 for Gastrointestinal Diseases

MOUNTAIN VIEW, Calif., Oct. 15 /PRNewswire/ -- ChemoCentryx, Inc., announced today that it has initiated a Phase I clinical trial of CCX025, the company's fourth investigational new drug and second orally administered compound that inhibits the chemokine receptor known as CCR9. Structurally distinct from Traficet-EN(TM) (CCX282-B; ChemoCentryx's CCR9 antagonist currently in a Phase II/III clinical trial for Crohn's disease), CCX025 strengthens ChemoCentryx's position in the CCR9 arena and expands the company's gastrointestinal franchise with the potential to pursue different clinical indications with discrete compounds.

"With the advancement of CCX025 into the clinic, ChemoCentryx can pursue a greater breadth of diseases associated with CCR9 receptor inhibition with the clear advantage of having two structurally distinct, very potent and highly-selective oral therapeutics," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "CCX025 is our fourth product candidate in the clinic, all discovered and developed at ChemoCentryx, and establishes our position as a leader in the industry in developing chemokine-based therapeutics."

The Phase I double-blind, placebo-controlled trial of CCX025 is being conducted in healthy male and female volunteers to evaluate the safety, tolerability and pharmacokinetics of CCX025 over a range of dose levels. In preclinical studies, the compound has been shown to be well-tolerated and highly selective. Like Traficet-EN, CCX025 is differentiated from existing inflammatory bowel disease therapies such as biologics (which are typically injected or infused), steroids and immunosuppressives and may offer a novel, safe and conveniently administered treatment option.

CCX025 and Traficet-EN are oral, highly-specific inhibitors of the chemokine receptor kn
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments?
3. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
4. New molecular imaging techniques may lead to advances in disease treatment
5. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
6. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
7. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
8. Human Genome Sciences Advances Oncology Portfolio
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Genetic Engineering & Biotechnology News reports on advances in miRNA
11. Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... Healthcare Conference in Miami, FL on ... David A. Ramsay , Chief Financial Officer, will provide a ... the "Investors" section of Halozyme,s corporate website at www.halozyme.com ... days following the event. To access the live webcast, please ...
(Date:3/3/2015)... LEXINGTON, Ky. (PRWEB) March 03, 2015 ... aligning their schedules for one event: the Alltech REBELation ... USA, from May 17-20. Now in its 31st year, ... people from 70 countries, and the opportunity to join ... week, March 7 at 11:59 p.m. EST, at which ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... the "Gene Therapy Market, 2015 - 2025" ... Therapy Market, 2015-2025" report provides an extensive study on ... research has been carried out in this field for ... therapies (four available in Asian markets; one approved in ...
(Date:3/3/2015)... Diagnostics Inc. (TSX:V: SQD), a life sciences company that ... advanced microarray diagnostics, today announced it has appointed ... team. In his capacity as CFO he will ... development stage to a commercially successful company including ... market strategy and to secure funding to drive ...
Breaking Biology Technology:Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3
... Inc. (Nasdaq: NVAX ) announced today the appointment ... Mr. Erck has more than twenty five years of experience ... as President and Chief Executive Officer of Iomai Corporation, a ... in 2008 by Intercell. Previously, Mr. Erck was President ...
... REYKJAVIK, Iceland, June 26 deCODE genetics,(Nasdaq: ... from the the Nasdaq,Hearing and Listing Review Council that the ... Nasdaq Global Market effective from the,opening of trading on Monday, ... symbol DCGN. , The reinstatement follows ...
... N.C., June 26 Syngenta Biotechnology, Inc. announced today ... Evogene, Ltd., focusing on identifying plant genes related to ... exclusive licensing rights to candidate genes discovered by Evogene ... is a soil parasite which attacks the roots of ...
Cached Biology Technology:Novavax Appoints Stanley Erck to Board of Directors 2Novavax Appoints Stanley Erck to Board of Directors 3deCODE Reinstated to Nasdaq Global Market 2deCODE Reinstated to Nasdaq Global Market 3Syngenta and Evogene to Collaborate on Soybean Nematode Resistance 2
(Date:2/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ) ... 2D Gesture Recognition Market 2015-2019" report to ... the Global 2D Gesture Recognition market to grow ... 2014-2019 The increased demand for gesture-enabled ... the major trends in the market. The growing ...
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... kidney disease (CKD) put them at a greater risk ... according to a new study released today in the ... Johns Hopkins University and the University of Maryland contributed ... of Kidney Disease and Hypertension (AASK) and the Chronic ...
... have long believed that microorganisms that produce methane swim toward ... has been too hard to prove in the lab. ... them to verify it for the first time, said Matthew ... co-author of a new paper describing the find. In ...
... 8, 2013 Research and ... addition of the "Europe Gesture Recognition ... Technology (2D, 3D, Ultrasonic, IR, Capacitive); Product ... (Germany, U.K., France, Italy, MEA)" report ...
Cached Biology News:Gene puts African-Americans at higher risk for kidney failure 2Montana State team overcomes challenges, proves that microbes swim to hydrogen gas 2Europe Gesture Recognition & Touchless Sensing Market (2013 - 2018) 2
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Silencer Pre-designed siRNAs, which are already designed ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Biology Products: